




Dysport®

Resource Catalogue

Why choose Dysport?



FDA-approved with more than a decade of clinical experience

INDICATIONS

Dysport (abobotulinumtoxinA) for injection is indicated for the treatment of:

- Spasticity in patients 2 years of age and older
- Cervical dystonia in adults

IMPORTANT SAFETY INFORMATION

Warning: Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Surrounded by Support

Whether you are new to Dysport or an experienced injector, Ipsen offers a wide range of educational and support resources for you, your practice, and your patients

Get

Extensive Resources

Product information, injection simulators, eLearning modules, patient journey videos, and more at CLIMB-training.com.

Trained

Peer-To-Peer Training

In person, virtual, and on-demand programs to answer questions specific to Dysport. Visit CLIMB-training.com or talk to your Ipsen representative for more information.

Get

Dysport Dosing Calculator

Online resource to help you calculate the recommended doses in selected muscles, and download a summary of the dosing plan.

Scan here to access



Started

IPSEN CARES®

Coverage, Access, Reimbursement, & Education Support for you and your patients. Eligible, commercially insured patients may pay as little as \$0 per prescription. Visit IPSENCARES.com for more information.*

Get

Product Acquisition

Information on Dysport acquisition, coding, billing, and reimbursement. See page 16 for more information.

Going

Dysport Injector Welcome Kit

A resource designed to help injectors model their experience with Dysport through observation and best practices from the pivotal clinical trials. See page 13 for more information.

*See the patient eligibility terms and conditions for the Dysport copay assistance program on page 19



MENU

[CLIMB-training.com](https://www.climb-training.com)

Continuum of Learning to Improve Management with Botulinum Toxin: a multi-tier learning continuum for physicians across all levels of experience to improve and expand clinical skills on the appropriate use of Dysport for the management of patients with spasticity and cervical dystonia.

Injection Education & Training

- Physical and virtual simulators (S.A.D.I.E., D.A.I.S.E.Y.)
- SynDaver™ Limbs (synthetic cadavers)
- Online and downloadable resources

Peer-to-Peer Education

- Live and virtual programs for injectors and PT/OT
- On-demand Programs
- See-one, Do-one Injection Training

Important Safety Information

Physician Resources

- Product Information
- Dosing and Dilution
- Patient Selection
- Dysport Injector Welcome kit

Preparing Your Practice

- Muscle posters
- Injection trackers
- Dilution poster
- Support for product acquisition, billing and coding

Patient Educational Resources

- Patient brochures
- Pediatric Adventure Book
- Doctor discussion guides

IPSEN CARES[®] Support for Providers

- Ipsen resources and support for product acquisition, billing and coding

IPSEN CARES[®] for Patients

- Coverage, reimbursement, and copay assistance*


*Not applicable for federally funded healthcare.



C.L.I.M.B.® EDUCATIONAL LEARNING PLATFORM


Take your injection expertise to the next level with the C.L.I.M.B.® Educational Learning Platform

By registering for the C.L.I.M.B.® Educational Learning Platform, you will gain access to Ipsen training opportunities, information about the management and treatment of conditions related to spasticity, and cervical dystonia and a wide range of Dysport related resources to support you and your office staff.




Injection Simulator Training

Learn about muscle selection, localization, Dysport dosing, injection techniques, and EMG response through virtual S.A.D.I.E. and D.A.I.S.E.Y.



Virtual S.A.D.I.E.
Spasticity Arm to Demonstrate Injection Education



Virtual D.A.I.S.E.Y.
Dystonic Anatomical Injection Simulator Educating You

To learn more, click here to visit CLIMB-training.com or scan QR code.



EMG=electromyography.




C.L.I.M.B.® EDUCATIONAL LEARNING PLATFORM (continued)

Patient Treatment Journey Videos

Follow physicians and their patients with spasticity or cervical dystonia along their treatment journey with Dysport including:


- Signs and symptoms
- Goal setting
- Injection
- PT/OT
- 4-week follow-up
- Reinjection



Disease State and Product E-Learning Modules


Disease State and Dysport Educational E-Learning Modules for Adult and Pediatric Spasticity

- Certificate of completion after each module!



Dosing and Dilution Webinars

Listen as your peers share their experiences with Dysport for the management of adult and pediatric spasticity and adult cervical dystonia. Receive insights regarding patient evaluation, Dysport dosing, and dose adjustment.



Resource Center

Materials to support your learning journey and to assist you with every aspect related to Dysport and your patients

- Product Information
- Dysport Resource Guide
- Clinical Overviews
- Dosing Guide
- Patient Profiles
- Muscle Posters
- Injection Records
- Patient Resources
- Dysport Injector Welcome Kit
- and more!



To learn more, click here to visit CLIMB-training.com or scan QR code.



OT=occupational therapy; PT=physical therapy.

INJECTION EDUCATION & TRAINING

Injection Simulators


Take your injection practice to the next level with S.A.D.I.E. (Spasticity Arm to Demonstrate Injection Education) and D.A.I.S.E.Y. (Dystonic Anatomical Injection Simulator Educating You).

These educational tools are used to visualize and target muscles using EMG technology and help learn Dysport dosing for the recommended muscles for upper limb spasticity and cervical dystonia.


Virtual S.A.D.I.E. and D.A.I.S.E.Y.

Virtual injection simulators available on CLIMB-training.com

Please note, it is recommended that you are trained by an Ipsen representative prior to accessing the virtual S.A.D.I.E. and D.A.I.S.E.Y. tools.




Also available with syringe stylus for a more tactile experience
In person with an Ipsen representative



Physical S.A.D.I.E. and D.A.I.S.E.Y.

Physical injection simulators for large group trainings and at major congresses



To learn more, contact your Ipsen representative.

Injection Education & Training (continued)

Upper and Lower SynDaver™ Limbs

Realistic synthetic cadaver limbs, SynDaver mimics with high fidelity to reality the physical properties (e.g., resistance) of live tissues, to aid in the identification of topographical anatomic landmarks, and provide a real feel experience of an injection in the upper and lower limbs.

Contact your Ipsen representative for an expert-led guided course on relevant muscles, muscle anatomy (neuromuscular junction, end plates, insertion, origin, etc.), and functional anatomy related to spasticity.



Vehicle Vials

Vehicle vials to practice appropriate Dysport reconstitution and dilution, experience partial vacuum, and develop injection skills with SynDavers or injection pods.

Reconstituted practice vials available by request.



Vial does not contain active ingredient

To learn more, contact your Ipsen representative.


Injection Education & Training (continued)

Online and Downloadable Resources

Patient Treatment Journey Videos

Follow physicians and their patients with spasticity or cervical dystonia along their treatment journey with Dysport including:

- Signs and symptoms
- Goal setting
- Injection
- Physical and occupational therapy
- Follow-up appointments
- Reinjection



Dysport Dosing Calculator



Online resource to help you calculate the recommended doses in selected muscles, and download a summary of the dosing plan.

Scan here to access



To learn more, click here to visit CLIMB-training.com or scan QR code.



PEER-TO-PEER EDUCATION

Dysport Speaker Bureau Programs

Programs available for Adult Spasticity, Pediatric Spasticity, and Cervical Dystonia



Group Meeting

60 to 90-minute virtual or in-person didactic presentation and product training by one of our faculty speakers.

Program now available for PT/OT audiences



On-demand

30 minute one-on-one conference call where one of our faculty speakers discusses appropriate patient selection, Dysport data, or Dysport dosing and dilution



See-one, Do-one

See-One

3-hour in-person or virtual preceptorship session on injection and clinical understanding of product use where you observe our faculty during patient injection treatment sessions.

Do-One

3-hour in-person or virtual mentorship session on injection, dosing and dilution, and appropriate product use where our faculty member observes you during patient injection treatment sessions.

Programs now available in person and virtually

To learn more, contact your Ipsen representative.

OT=occupational therapy; PT=physical therapy.

IMPORTANT SAFETY INFORMATION

Warning: Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Contraindications

Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow's milk protein, components in the formulation or infection at the injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a reaction occurs, discontinue Dysport and institute appropriate medical therapy immediately.

Warnings and Precautions

Lack of Interchangeability Between Botulinum Toxin Products.

The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products, and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Dysphagia and Breathing Difficulties

Treatment with Dysport and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant side effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Important Safety Information (continued)

Warnings and Precautions (continued)

Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction

The possibility of an immune reaction when injected intradermally is unknown. The safety of Dysport for the treatment of hyperhidrosis has not been established. Dysport is approved only for intramuscular injection.

Most Common Adverse Reactions

Adults with lower limb spasticity ($\geq 5\%$): falls, muscular weakness, and pain in extremity and with **upper limb spasticity** ($\geq 4\%$): muscular weakness.

Pediatric patients with lower limb spasticity ($\geq 10\%$): nasopharyngitis, cough and pyrexia and with **upper limb spasticity** ($\geq 10\%$): upper respiratory tract infection and pharyngitis.

Adults with cervical dystonia ($\geq 5\%$): muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.

Drug Interactions

Co-administration of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects, such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport.

Important Safety Information (continued)

Special Populations

Use in Pregnancy

There are no adequate and well-controlled studies in pregnant women. Dysport should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Based on animal data, Dysport may cause fetal harm.

Pediatric Use

The safety and effectiveness of Dysport injected into proximal muscles of the lower limb for the treatment of spasticity in pediatric patients has not been established. Based on animal data Dysport may cause atrophy of injected and adjacent muscles; decreased bone growth, length, and mineral content; delayed sexual maturation; and decreased fertility.

Geriatric Use

In general, elderly patients should be observed to evaluate their tolerability of Dysport, due to the greater frequency of concomitant disease and other drug therapy. Subjects aged 65 years and over who were treated with Dysport for lower limb spasticity reported a greater percentage of fall and asthenia as compared to those younger (10% vs. 6% and 4% vs. 2%, respectively).

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Ipsen at 1-855-463-5127. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


PHYSICIAN RESOURCES

The Dysport Injector Welcome Kit

An intuitive kit designed to develop a more experienced Dysport injector

- Getting your patient started
- Model your experience on Dysport pivotal trials
- Patient injection record and progress tracker
- Patient analysis guide
- Reporting


Coming soon for PS and CD



Product Information

Product Monographs (AS, CD, and PS)

A product overview including molecular structure, MOA, clinical history and data from pivotal trials for the 3 indications, recommended dosing and dilution, as well as storage and handling.



Clinical Overviews (AS, CD, and PS)

Provides detailed data from pivotal clinical trials including efficacy and safety profile as well as dosing recommendations.



AS=adult spasticity; CD=cervical dystonia;
MOA=mechanism of action; PS=pediatric spasticity.

To learn more, click here to visit CLIMB-training.com or scan QR code.



Physician Resources (continued)

Dosing and Dilution

Dosing and Dilution Brochures


Brochures with detailed muscles and FDA-approved doses for the treatment of adult patients with spasticity or cervical dystonia.

The pediatric brochure includes a weight-based dosing slider for the appropriate dosing of Dysport for your pediatric patients aged 2 years and older.



Patient Injection Records

Injection records for the 3 indications that can be uploaded to EMR systems to record Dysport doses and muscles injected at each cycle.



Reconstitution and Muscle Posters

Visual aid of Dysport reconstitution and dilution instructions for your office.

Visual aid to review doses and muscles recommended for injection.



To learn more, click here to visit CLIMB-training.com or scan QR code.



EMR=electronic medical record; FDA=Food and Drug Administration.

Physician Resources (continued)

Dosing and Dilution (continued)

Dysport Dosing Calculator

Online resource to help you calculate the recommended doses in selected muscles, and download a summary of the dosing plan.


Scan here to access



Patient Selection


Dysport Patient Profile (AS)

Physician brochure describing examples of adult patients with upper limb spasticity and lower limb spasticity to aid in patient selection and the management of patients receiving Dysport.



On-demand Program Specific to Patient Selection

Scheduled one-on-one meetings with a Dysport injector to answer to your questions about Dysport utilization and patient selection across the 3 indications.



Have a specific question regarding dosing and dilution? Request an on-demand program to ask a Dysport injector directly through CLIMB or contact your Ipsen professional!

To learn more, click here to visit CLIMB-training.com or scan QR code.



AS=adult spasticity

PREPARING YOUR PRACTICE


Acquisition, Billing & Reimbursement

The Dysport Resource Guide provides information on acquisition options for Dysport, billing and coding support, and an overview of IPSEN CARES® for copay and reimbursement.



Electronic Health Records Guide


A flashcard that includes a step by step process for office staff on how to access Dysport in their EHR database.



Office Posters and Patient Injection Records

Posters of Dysport dosing, reconstitution and approved muscles for injection for quick reference at your office.

Injection records to help track Dysport units injected into each muscle. Billing and vial tracking information are also included to support your office staff.



To learn more, click here to visit CLIMB-training.com or scan QR code.



EHR=electronic health record.

PATIENT EDUCATIONAL RESOURCES


Patient Brochures

Informative brochures for patients and parents/caregivers about the management of spasticity or cervical dystonia. The brochures provide questions for patients to ask their doctors, goal-setting ideas, and what can be expected with Dysport treatment.



Patient/Caregiver Discussion Guides

Informative brochures for patients and parents/caregivers about the management of spasticity or cervical dystonia. The guides provide questions for patients to ask their doctors, goal-setting ideas, and what can be expected with Dysport treatment.



Dysport Pediatric Spasticity Adventure Book

This book provides support to your pediatric patients living with spasticity and their care team. It offers fun activities, tips for injection days, goal-setting ideas, and more.



To learn more, click here to visit CLIMB-training.com or scan QR code.




IPSEN CARES

Reimbursement and IPSEN CARES® (Coverage, Access, Reimbursement & Education Support)

The IPSEN CARES® program offers patient support for eligible and enrolled patients prescribed Dysport, including services such as benefits verification in as little as 1 business day.

Contact your Ipsen Regional Reimbursement Director (RRD) for coding, coverage, and payment information



Copay Assistance Program

Helping eligible patients get access to their prescribed medications with the information and support they need.

See the patient eligibility terms and conditions for the Dysport copay assistance program on page 19



Acquisition, coding, and billing

The Dysport Resource Guide provides information on acquisition, coding, coverage, and billing options for Dysport, and an overview of IPSEN CARES® for copay and reimbursement.



IPSENCARES®
Coverage, Access, Reimbursement & Education Support

IPSEN CARES is a registered trademark of Ipsen S.A.
DYSPORE is a registered trademark of Ipsen Biopharm Limited. All other trademarks are the property of their respective owners.

To learn more, click here to visit IPSENCARES.com or scan QR code.



IPSEN CARES

Reimbursement and IPSEN CARES® (continued)

(Coverage, Access, Reimbursement & Education Support)


The Text Message Program Helps Patients Along Their Journey as a Member of IPSEN CARES:

Support is only a text message away!

The Text Message Program has many different types of messages to help patients stay current on their prescribed medication plan:

- ✓ Refills at patient's Specialty Pharmacy
- ✓ IPSEN CARES re-enrollment
- ✓ Changes to patient's insurance
- ✓ HCP appointment reminders

Patients can opt-in to the Text Message Program on the IPSEN CARES enrollment form!



*Patient Eligibility & Terms and Conditions: Patients are not eligible for copay assistance through IPSEN CARES® if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TRICARE (collectively, "Government Programs"), or where prohibited by law. Patients residing in Massachusetts, Minnesota, Michigan, or Rhode Island can only receive assistance with the cost of Ipsen products but not the cost of related medical services (injection). Patients receiving assistance through another assistance program or foundation, free trial, or other similar offer or program, are not eligible for the copay assistance program during the current enrollment year.

Cash-pay patients are eligible to participate. "Cash-pay" patients are defined for purposes of this program as patients without insurance coverage or who have commercial insurance that does not cover Dysport®. Medicare Part D enrollees who are in the prescription drug coverage gap (the "donut hole") are not considered cash-pay patients and are not eligible for copay assistance through IPSEN CARES®. For patients with commercial insurance who are not considered to be cash-pay patients, the maximum copay benefit amount per prescription is an amount equal to the difference between the annual maximum copay benefit of \$5,000 and the total amount of copay benefit provided to the patient in the Dysport® Copay Program. In any calendar year commencing January 1, the maximum copay benefit amount paid by Ipsen Biopharmaceuticals, Inc. will be \$5,000, covering no more than four (4) Dysport® treatments. For cash-pay patients, the maximum copay benefit amount per eligible Dysport® treatment is \$1,250, subject to the annual maximum of \$5,000 in total. There could be additional financial responsibility depending on the patient's insurance plan.

Patient or guardian is responsible for reporting receipt of copay savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled through the program, as may be required. Additionally, patients may not submit any benefit provided by this program for reimbursement through a Flexible Spending Account, Health Savings Account, or Health Reimbursement Account. Ipsen reserves the right to rescind, revoke, or amend these offers without notice at any time. Ipsen and/or RxCrossroads by McKesson are not responsible for any transactions processed under this program where Medicaid, Medicare, or Medigap payment in part or full has been applied. Data related to patient participation may be collected, analyzed, and shared with Ipsen for market research and other purposes related to assessing the program. Data shared with Ipsen will be de-identified, meaning it will not identify the patient. Void outside of the United States and its territories or where prohibited by law, taxed, or restricted. This program is not health insurance. No other purchase is necessary.

IPSENCARES®

Coverage, Access, Reimbursement & Education Support

IPSEN CARES is a registered trademark of Ipsen S.A.
DYSPORE is a registered trademark of Ipsen Biopharm Limited. All other trademarks are the property of their respective owners.

To learn more, click here to visit IPSENCARES.com or scan QR code.





Dysport® (abobotulinumtoxinA) for injection, for intramuscular use 300- and 500-Unit vials.
DYSPOORT is a registered trademark of Ipsen Biopharm Limited. IPSEN CARES is a registered trademark of Ipsen S.A.
©2022 Ipsen Biopharmaceuticals, Inc. December 2021 DYS-US-006835



What would more time between injections mean to your patients?

Adult Spasticity



Significantly reduced muscle tone at week 4

Cervical Dystonia



Significantly reduced abnormal head position and neck pain at week 4

Pediatric Spasticity



Significantly reduced muscle tone at week 4 (PLLS) and week 6 (PULS)

Duration

Dysport® offered sustained symptom* relief beyond minimum time to retreatment across all indications

Dosing

Dysport® has a wide FDA-approved dosing range, allowing for flexibility to customize subsequent doses based on patient response.

Safety

Dysport® has a well-characterized safety profile across all doses in patients with spasticity or cervical dystonia

- Retreatment with Dysport should not occur in intervals of less than 12 weeks for adult/pediatric spasticity or cervical dystonia
- The maximum recommended total dose per treatment session (upper and lower limb combined) in adults is 1,500 Units
- The recommended initial dose for CD in adults is 500 Units given intramuscularly as a divided dose among the affected muscles
- For unilateral PULS, the maximum recommended total dose per treatment session is 16 Units/kg or 640 Units, whichever is lower
- For unilateral PLLS, the maximum recommended total dose per treatment session is 15 Units/kg or 1,000 Units, whichever is lower
- For bilateral PLLS, the maximum recommended total dose per treatment session is 30 Units/kg or 1,000 Units, whichever is lower

The efficacy and safety of Dysport has been studied across 6 FDA registrational clinical trials in a total of 870 patients

MAS Score

↓ Reduced muscle tone at week 4[†]

Time to retreatment was

12 to 16 weeks

for the majority of adult patients with spasticity



Most commonly observed adverse reactions in ULS were muscle weakness (>4%), and in LLS were falls, muscular weakness and pain in extremity (>5%)

TWSTRS Score

⌚ Improvement in abnormal head position at week[‡]

Median time to retreatment was

14 weeks

for adult patients cervical dystonia



Most commonly observed adverse reactions were muscle weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (>5%)

MAS Score

↓ Reduced muscle tone at week 4[§]

Time to retreatment was

24 weeks

18 to ≥ 24 weeks

for most pediatric patients with ULS

for most pediatric patients with LLS



Most commonly observed adverse reactions in PULS upper respiratory tract infection and pharyngitis (>10%), and in PLLS were nasopharyngitis, cough, and pyrexia (>5%)

[†]Data from clinical trials involving 412 adult patients with spasticity treated with Dysport, [‡]92 patients with cervical dystonia treated with Dysport, and [§]366 pediatric patients with spasticity treated with Dysport.

LLS=lower limb spasticity; ULS=upper limb spasticity; PLLS=pediatric lower limb spasticity; PULS=pediatric upper limb spasticity

FDA= Food and Drug Administration

*Symptoms of spasticity can include abnormal increase in muscle tone and muscle spasms. Symptoms of cervical dystonia can include abnormal head position and neck pain.

ADULT Disease State Training

Pathophysiology of Spasticity

- Overview of spasticity
- Upper limb spasticity
- Lower limb spasticity
- The cycle of spasticity and impact on patients

Structuring Treatment and Patient Goal Setting in Spasticity

- Key members of the multi-professional team
- Principles of spasticity management
- Defining the right goals to measure treatment improvement

DYSPORT® TRAINING

Dysport for the Treatment of Adult Spasticity

- Registrational trial data for AULS treatment
- Registrational trial data for ALLS treatment

Clinical Use of Dysport

- Doses and muscles approved for injection
- Preparation of Dysport
- Resources to aid clinical practice

PEDIATRIC Disease State Training

Causes and Consequences of Spasticity in Children

- Overview of spasticity
- Causes of spasticity in children
- Common postures in pediatric spasticity
- The long-term impact
- The patient's perspective

Assessment of Spasticity in Children

- Importance of assessing spasticity
- Measurement scoring scales
- Selecting and performing assessments

Multidisciplinary Team and Goal Setting

- Key members of the multidisciplinary team
- Principles of spasticity management
- Defining the right goals to measure treatment improvement

Diagnosis and Assessment of Spasticity

- Assessing patients with spasticity symptoms
- Goals of spasticity management
- Selecting a spasticity measure
- Measurement scoring scales

Treatment of Adult Spasticity

- Physical and focal interventions in spasticity management
- Medical management of adult spasticity
- BoNT-A for treatment of spasticity
- Treatment timing and patient selection
- Suboptimal response to BoNT-A treatment

Cervical Dystonia- "Coming Soon!"

Approaches to Care for Children With Spasticity

- Key principles of spasticity treatment
- Physical treatments and focal interventions
- Oral agents and intrathecal options
- Denervation
- Surgical techniques

Dysport Transition of Care

- Transition of care: Gaps, goals, and considerations
- Key elements of a transition program
- Resources for transitioning care

DYSPORT® TRAINING

Dysport for the Treatment of Pediatric Spasticity

- Registrational trial data for PULS treatment
- Registrational trial data for PLLS treatment

Clinical Use of Dysport

- Doses and muscles approved for injection
- Preparation of Dysport
- Resources to aid clinical practice

ALLS=adult lower limb spasticity; AULS=adult upper limb spasticity; BoNT-A=botulinum toxin type A; PLLS=pediatric lower limb spasticity; PULS=pediatric upper limb spasticity.

Sample CMS-1500 Claim Form

Physician Office

Dysport and the associated services provided in a physician's office are billed on the CMS-1500 claim form or its electronic equivalent. A sample CMS-1500 claim form for billing Dysport is provided below.

The sample claim form provided below is only an example. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered.

Providers should contact third-party payers for specific information regarding their coding, coverage, and payment policies.

Box 21

Enter the appropriate ICD-10-CM diagnosis code, eg, G81.11 for spastic hemiplegia affecting right dominant side (upper limb spasticity).
Code to the highest level of specificity. ICD-10-CM diagnosis codes contain 3-7 digits. It is recommended that providers verify each payer's specific coding requirements prior to injecting.

Box 23

Input the authorization number if obtained from the insurance provider.

Box 24E

For each code, insert the number corresponding to the appropriate diagnosis code in field 21.

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)														20. OUTSIDE LAB? <input type="checkbox"/> YES <input type="checkbox"/> NO		\$ CHARGES															
Dysport, abobotulinumtoxinA														21. ICD-10-CM DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line below (24E))		ICD-10-CM		22. EXEMPTION CODE		ORIGINAL REF. NO.											
A. G81.11		B.		C.		D.		E.		F.		G.		H.		I.		J.													
23. PRIOR AUTHORIZATION NUMBER														00000000																	
24. A. DATE(S) OF SERVICE														B. PLACE OF SERVICE		C. EMG		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)				E. DIAGNOSIS POINTER		\$ CHARGES		H. UNITS		I. ID		J. RENDERING PROVIDER ID #	
From		To																													
1		02 01 19		02 01 19		11		J0586				A		100		NPI															
2		02 01 19		10 01 19		11		64642				A		1		NPI															
3																															
4																															

Box 24A

In the shaded area, list the N4 qualifier, the 11-digit drug NDC#, the unit of measurement qualifier, and dosage.
Example:
15054050001UN500.00
(Note: some payers may request the NDC number be listed in box 19.)
In the non-shaded area, list the date of service.

Box 24D

Include the appropriate CPT codes to report administration procedures, eg, 64642 (chemodestruction of 1 extremity, 1-4 muscle[s], eg, for upper limb spasticity).
For Dysport, use the unique HCPCS code required by payer. Also, include appropriate modifiers as instructed by payer.

Box 24G

Report the appropriate number of units actually administered and the appropriate number of HCPCS units for Dysport J0586 (500-unit vial = 100 billing units, and 300-unit vial = 60 billing units).

Note: For Dysport obtained through a Specialty Pharmacy, no charges for the drug should be billed by the provider. However, inclusion of the HCPCS code (J0586) is recommended to designate the drug administered and number of units administered. Consult with the individual payer to determine the appropriate method of documenting and billing for drugs obtained through a Specialty Pharmacy.

The diagnosis and procedure codes listed on this sample claim form are provided as examples only.

Dysport® (abobotulinumtoxinA) for injection, for intramuscular use 300- and 500-Unit vials.
DYSPOORT is a registered trademark of Ipsen Biopharm Limited. IPSEN CARES is a registered trademark of Ipsen S.A.
©2022 Ipsen Biopharmaceuticals, Inc. January 2022 DYS-US-006835